References
- Alho, H., Sinclair, D., Vuori, E., & Holopainen, A. (2007). Abuse liability of buprenorphine/naloxone tablets in untreated IV drug users. Drug Alcohol Dependence, 88, 75–78
- Ducharme, S., Fraser, R., & Gill, K. (2012). Update on the clinical use of buprenorphine in opioid-related disorders. Canadian Family Physician, 58, 37–41
- Fazel, S., Bains, P., & Doll, H. (2006). Substance abuse and dependence in prisoners: A systematic review. Addiction, 101, 181–191
- George, S., & Moreira, K. (2008). Buprenorphine snorters: A case series. Journal of Substance Use, 13, 131–137
- HM Prison Service. (2000). Categorisation and allocation (PSO 0900). London: HM Prison Service
- Horyniak, D., Dietze, P., Larance, B., Winstock, A., & Degenhardt, L. (2011). The prevalence and correlates of buprenorphine inhalation amongst opioid substitution (OST) clients in Australia. International Journal of Drug Policy, 22, 167–171
- Middleton, L.S., Nuzzo, P.A., Lofwall, M.R., Moody, D.E., & Walsh, S.L. (2011). The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction, 106, 1460–1473
- Ministry of Justice. (2007). A survey of buprenorphine misuse in prison. London: Ministry of Justice
- Montesano, F., Zaccone, D., Battaglia, E., Genco, F., & Mellace, V. (2010). Therapeutic switch to buprenorphine/naloxone from buprenorphine alone. Clinical Drug Investigation, 30, 13–19
- Penfold, C., Turnbull, P., & Webster, R. (2005). Tackling prison drug markets: An exploratory qualitative study. Home Office Online Research Report 39/05. London: Home Office
- Reckitt Benckiser Pharmaceuticals Inc. (2014). Multiple dose study of blockade of opioid effects of subcutaneous injections of buprenorphine in participants with opioid use disorder. Retrieved from http://clinicaltrials.gov/ct2/show/NCT02044094?term=Buprenorphine+naloxone+depot+injection&rank=1
- Simojoki, K., Lillsunde, P., Lintzeris, N., & Alho, H. (2010). Bioavailability of buprenorphine from crushed and whole buprenorphine (Subutex) tablets. European Addiction Research, 16, 85–90
- Simojoki, K., Vorma, H., & Alho, H. (2008). A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone). Substance Abuse Treatment Prevention, and Policy, 3, 16. doi: 10.1186/1747-597X-3-16
- Smith, M., Bailey, J., Woody, G., & Kleber, H. (2007). Abuse of buprenorphine in the United States: 2003-2005. Journal of Addictive Diseases, 26, 107–111
- Strain, E.C., Moody, D.E., Stroller, K.B., Walsh, S.L., & Bigelow, G.E. (2004). Relative bioavailability of different buprenorphine formulations under chronic conditions. Drug Alcohol Dependence, 74(1), 37–43
- Tompkins, C.N.E., Wright, N.M.J., Waterman, M.G., & Sheard, L. (2009). Exploring prison buprenorphine misuse in the United Kingdom: A qualitative study of former prisoners. International Journal of Prison Health, 5, 71–87
- Walmsley, R. (2013). World prison population list (10th ed.). London: International Centre for Prison Studies
- White, J., Bell, J., Saunders, J., Williamson, P., Makowska, M., Farquharson, A., & Beebe, K. (2009). Open-label dose-finding trial of buprenorphine implants (Probuphine)(R) for treatment of heroin dependence. Drug Alcohol Dependence, 103, 37–43
- Wright, N.M.J., Mohammed, Z., & Hughes, G.J. (2014). Comparative prices of diverted buprenorphine/naloxone and buprenorphine in a UK prison setting: A cross-sectional survey of drug using prisoners. Drug Alcohol Dependence, 144, 254–258